Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naïve HIV-Infected Participants.
Schürmann D, Hüser A, Pfäfflin F, Cilissen C, De Lepeleire I, Larson PJ, Anderson MS, Rizk ML, Hofmann J, Däumer M, Stegemann MS, Stoch SA, Wagner F, Iwamoto M. Schürmann D, et al. Among authors: rizk ml. AIDS Res Hum Retroviruses. 2025 Jan;41(1):11-19. doi: 10.1089/AID.2023.0152. Epub 2024 Oct 3. AIDS Res Hum Retroviruses. 2025. PMID: 39291814 Clinical Trial.
Molnupiravir: Mechanism of action, clinical, and translational science.
Maas BM, Strizki J, Miller RR, Kumar S, Brown M, Johnson MG, Cheng M, De Anda C, Rizk ML, Stone JA. Maas BM, et al. Among authors: rizk ml. Clin Transl Sci. 2024 Feb;17(2):e13732. doi: 10.1111/cts.13732. Clin Transl Sci. 2024. PMID: 38593352 Free PMC article. Review.
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Bihorel S, Cao Y, Chawla A, Birger R, Maas BM, Gao W, Roepcke S, Sardella S, Humphrey R, Kondragunta S, Jayaraman B, Martinho M, Painter W, Painter G, Holman W, De Anda C, Brown ML, Johnson MG, Paschke A, Rizk ML, Stone JA. Bihorel S, et al. Among authors: rizk ml. CPT Pharmacometrics Syst Pharmacol. 2023 Dec;12(12):1859-1871. doi: 10.1002/psp4.13031. Epub 2023 Oct 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37798914 Free PMC article. Clinical Trial.
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
Roberts JA, Nicolau DP, Martin-Loeches I, Deryke CA, Losada MC, Du J, Patel M, Rizk ML, Paschke A, Chen LF. Roberts JA, et al. Among authors: rizk ml. JAC Antimicrob Resist. 2023 Mar 4;5(2):dlad011. doi: 10.1093/jacamr/dlad011. eCollection 2023 Apr. JAC Antimicrob Resist. 2023. PMID: 36880088 Free PMC article.
Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
Li D, Sabato PE, Guiastrennec B, Ouerdani A, Feng HP, Duval V, De Anda CS, Sears PS, Chou MZ, Hardalo C, Broyde N, Rizk ML. Li D, et al. Among authors: rizk ml. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0089521. doi: 10.1128/AAC.00895-21. Epub 2021 Sep 13. Antimicrob Agents Chemother. 2021. PMID: 34516243 Free PMC article.
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development.
van den Berg P, Gao W, Ahsman MJ, Arrington L, Kesisoglou F, Miller R, Post TM, Rizk ML. van den Berg P, et al. Among authors: rizk ml. CPT Pharmacometrics Syst Pharmacol. 2021 Jul;10(7):658-670. doi: 10.1002/psp4.12644. Epub 2021 Jun 18. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33934558 Free PMC article.
53 results